Trovato M, Berardinis PD. Novel antigen delivery systems. World J Virology 2015; 4(3): 156-168 [PMID: 26279977 DOI: 10.5501/wjv.v4.i3.156]
Corresponding Author of This Article
Piergiuseppe De Berardinis, PhD, Institute of Protein Biochemistry, National Research Council, Via Pietro Castellino 111, 80131 Naples, Italy. p.deberardinis@ibp.cnr.it
Research Domain of This Article
Virology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Virology. Aug 12, 2015; 4(3): 156-168 Published online Aug 12, 2015. doi: 10.5501/wjv.v4.i3.156
Novel antigen delivery systems
Maria Trovato, Piergiuseppe De Berardinis
Maria Trovato, Piergiuseppe De Berardinis, Institute of Protein Biochemistry, National Research Council, 80131 Naples, Italy
Author contributions: All authors contributed to this paper and they approved the final version of the article.
Supported by The grants from Nos. NIH R01AI AI074379 and MIUR-PON 01_00117.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Piergiuseppe De Berardinis, PhD, Institute of Protein Biochemistry, National Research Council, Via Pietro Castellino 111, 80131 Naples, Italy. p.deberardinis@ibp.cnr.it
Telephone: +39-081-6132566
Received: January 26, 2015 Peer-review started: February 5, 2015 First decision: April 27, 2015 Revised: June 23, 2015 Accepted: July 29, 2015 Article in press: August 3, 2015 Published online: August 12, 2015 Processing time: 198 Days and 11.8 Hours
Core Tip
Core tip: Several promising strategies of vaccination have been proposed over the past years to treat and/or prevent infectious and cancer diseases. These include live attenuated or inactivated viral vaccines, recombinant viral vectors, DNA vaccines, subunit vaccines, nanoparticle carriers, and lipid-based delivery systems such as liposomes and virosomes. Although some of these suffer from certain limitations (e.g., safety concerns, weak immunogenicity, adverse side-effects associated with adjuvants), recent advances in vaccine technology have provided further insights for guiding vaccine design. Here, we review the current status of antigen delivery systems with emphasis on a versatile and immunogenic vaccine delivery candidate: the “E2 scaffold”.
